SPECIAL FEATURES

CCR Translations

6061 Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed
Dung T. Le and Elizabeth M. Jaffee
See related article, p. 6286

6064 Test-Firing Ammunition for Spliceosome Inhibition in Cancer
Scott M. Dehm
See related article, p. 6296

CCR Perspectives in Drug Approval

6067 Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary

Molecular Pathways

6074 Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer
Louise R. Howe, Kotha Subbaramaiah, Clifford A. Hudis, and Andrew J. Dannenberg

6084 Molecular Pathways: Induction of Polyploidy as a Novel Differentiation Therapy for Leukemia
Diane S. Krause and John D. Crispino

Review

6089 Lessons Learned from Radiation Oncology Clinical Trials
Fei-Fei Liu, for the workshop participants, Paul Okunieff, Eric J. Bernhard, Helen B. Stone, Stephen Yoo, C. Norman Coleman, Bhadrasain Vikram, Martin Brown, John Buatti, and Chandan Guha
Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
Aizea Morales-Kastresana, Miguel F. Sammanned, Inmaculada Rodriguez, Asis Palazon, Ivan Martinez-Forero, Sara Labiano, Sandra Hervas-Stubbs, Bruno Sangro, Carmen Ochoa, Ana Rouzaut, Arantza Argüékueta, Elizabet Bolaños, Maria Jure-Kunkel, Ines Güttgemann, and Ignacio Melero

6151

Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Sara A. Flanigan, Todd M. Pitts, Timothy P. Newton, Gillian N. Kulikowski, Aik Choon Tan, Martine C. McManus, Anna Sprefico, Maria I. Kachaeva, Heather M. Selby, John J. Tentler, S. Gail Eckhardt, and Stephen Leong

6219

JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease
Emeline Evrot, Nicolas Ebel, Vincent Romanet, Claudia Roelli, Rita Andraos, Zhiyan Qian, Arno Dölemeier, Ernesta Dammassa, Dario Sterker, Robert Cozens, Francesco Hofmann, Masato Murakami, Fabienne Buffert, and Thomas Radimerski

6230

IMAGING, DIAGNOSIS, PROGNOSIS

Associations between Single-Nucleotide Polymorphisms in the PI3K–PTEN–AKT–mTOR Pathway and Increased Risk of Brain Metastasis in Patients with Non–Small Cell Lung Cancer
Qianxia Li, Ju Yang, Qianqian Yu, Huanlei Wu, Bo Liu, Huihua Xiong, Guangyuan Hu, Jing Zhao, Xianglin Yuan, and Zhongxing Liao

6252

Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma
Ignacio I. Wistuba, Carmen Behrens, Francesca Lombardi, Susanne Wagner, Junya Fujimoto, M. Gabriela Raso, Lorenzo Spaggiari, Domenico Galetta, Rohyn Riley, Elisha Hughes, Julia Reid, Zaina Sangale, Steven G. Swisher, Neda Kalhor, Cesar A. Moran, Alexander Gustin, Jerry S. Lanchbury, Massimo Barberis, and Edward S. Kim

6261
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6313</td>
<td>Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia</td>
<td>Mauricio Burotto, Maryalice Stetler-Stevenson, Exgeny Arons, Hong Zhou, Wyndham Wilson, and Robert J. Kreitman</td>
</tr>
<tr>
<td>6296</td>
<td>Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors</td>
<td>Ferry A.L.M. Eskens, Francisco J. Ramos, Herman Burger, James P. O'Brien, Adelaidea Priera, Maja J.A. de Jonge, Yoshidamaru Mizui, Erik A.C. Wiemer, Maria Josepa Carreras, José Baselga, and Josep Taberner</td>
</tr>
<tr>
<td>6331</td>
<td>Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response</td>
<td>Klaus G. Grewank, Henrik Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steuhl, Lisa Zimmer, and Dirk Schadendorf</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

Cellular internalization of siRNA (red fluorescence) delivered by the nanocarrier (green fluorescence) specifically targeted to cancer cells. Superimposition of red (siRNA) and green (nanocarrier) fluorescence images gives yellow color. For details, see the article by Shah and colleagues on page 6193 of this issue.
Clinical Cancer Research

19 (22)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/22

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.